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The global burden of antibiotic resistance is tremendous and, without new anti-infective strategies, will continue
to increase in the coming decades. Despite the growing need for new antibiotics, few pharmaceutical companies
today retain active antibacterial drug discovery programmes. One reason is that it is scientifically challenging to
discover new antibiotics that are active against the antibiotic-resistant bacteria of current clinical concern.
However, the main hurdle is diminishing economic incentives. Increased global calls to minimize the overuse
of antibiotics, the cost of meeting regulatory requirements and the low prices of currently marketed antibiotics
are strong deterrents to antibacterial drug development programmes. New economic models that create incen-
tives for the discovery of new antibiotics and yet reconcile these incentives with responsible antibiotic use are long
overdue. DRIVE-AB is aE9.4 million public–private consortium, funded by the EU Innovative Medicines Initiative,
that aims to define a standard for the responsible use of antibiotics and to develop, test and recommend new
economic models to incentivize investment in producing new anti-infective agents.
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Introduction
Although difficult to calculate, the worldwide burden of antibiotic
resistance is high.1 Despite great improvements in infection control,
antibiotic stewardship and vaccine technology during the last dec-
ade, antibiotics remain a cornerstone of infectious disease therapy.
Indeed, these agents are the hidden backbone of advanced medical
care: surgical procedures, transplant and geriatric medicine, critical
care and cancer chemotherapy all rely on their effectiveness for suc-
cessful clinical outcomes.2 Yet as antibiotic resistance increased
across the globe, most pharmaceutical companies closed down
their antibiotic research and development (R&D) units. In 1980,
there were more than 25 pharmaceutical companies with active
antibacterial drug discovery programmes3; today only a few of
the largest companies remain active in the field. As a consequence,
during the last two decades, a substantial gap in the discovery of
antibacterial drugs has been created, which is responsible for the
current lack of newly approved systemic antibacterial agents
(Figure 1). In particular, the need for effective agents targeting
MDR Gram-negative bacteria grows dire, with no agent of a new
class or with a new mode of action in late clinical development.4
Reasons for the lack of new antibiotics
There are several reasons for the dry pipeline. Scientifically, the
‘low-hanging fruits’ have been plucked; new breakthroughs are
elusive and expensive.5 Another major challenge lies in economic
incentives for investment in this area, or the growing lack thereof,
compared with other therapeutic fields. Developing novel drugs for
infections caused by MDR bacteria is challenging; meanwhile, the
pharmaceutical industry is increasingly faced with a large number
of inexpensive off-patent antibiotics, as well as tightening restric-
tions for placement on hospital formularies and limitations on
the pricing of new antibiotics. Healthcare payers are neither accus-
tomed nor prepared to reimburse antibiotics at prices that provide
incentives to start or maintain antibacterial drug development
programmes.6
Traditionally, in order to recover R&D costs and ensure financial
returns, pharmaceutical companies aim to maximize the sales
potential, and thus the consumption, of their products. In the
case of antibiotics, however, this simple sales-based model runs
counter to the public health mandate to ‘steward’ the consumption
of these drugs in order to preserve their efficacy. Any approach to
the problem of the lack of incentives for new antibiotic develop-
ment must address the parallel challenge of the lack of short-term
incentives for their appropriate use.7 Initiatives to improve the
development pipeline for new antibiotics have been proposed
and some are currently being implemented on both sides of the
Atlantic [e.g. the Generating Antibiotics Incentives Now (GAIN)
Act in the USA, and the Innovative Medicines Initiative (IMI) in
Europe].8 – 10 Of particular note, the UK government has recently
announced a financial review of economic issues surrounding anti-
microbial resistance and the plan for encouraging and accelerating
the discovery and development of new generations of antibiotics.11
Moreover, there are many strategies to minimize the misuse of
antibiotics.12,13
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Figure 1. Illustration of the ‘discovery void’. The dates indicated are those of the reported initial discovery or patent. Figure reprinted with permission.5
Table 1. Partners of the DRIVE-AB Initiative
Organization Main participant names Type of organization Country
BSAC Laura Piddock public UK
Center for Anti-Infective Agents Ursula Theuretzbacher private Austria
Chatham House Charles Clift private UK
London School of Economics and Political Science Elias Mossialos public UK
Norwegian Institute of Public Health John-Arne Røttingen public Norway
Tel-Aviv Sourasky Medical Center Yehuda Carmeli public Israel
The Radboud University Nijmegen Medical Centre Inge Gyssens public Netherlands
University of Antwerp Herman Goossens public Belgium
University of Geneva Stephan Harbarth public Switzerland
University of Heidelberg Timo Goeschl public Germany
University of Lorraine Ce´line Pulcini public France
University of Rijeka Medical Faculty Vera Vlahovic´-Palcˇevski public Croatia
University of Strathclyde Alec Morton and Ramanan Laxminarayan public UK
University of Tu¨bingen Evelina Tacconelli public Germany
Uppsala University Francesco Ciabuschi public Sweden
Wageningen University Justus Wesseler public Netherlands
Astellas Pharma Europe Ltd Chris Longshaw private UK
AstraZeneca Judith Hackett and John Rex private Sweden/USA
Cubist Pharmaceuticals Barry Eisenstein private USA
F. Hoffmann-La Roche Ltd Ka Lum and Brigitte Nolet private Switzerland
GlaxoSmithKline R&D David Findlay private UK
Pfizer Ltd Charles Knirsch private USA
Sanofi-Aventis R&D Sue Cheng private France
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None of these initiatives, however, has linked incentives for the
development of new antibiotics to the responsible use of these
scarce resources; none specifically addresses the conflict trad-
itionally inherent in these two objectives. Thus, there is an urgent
need to foster a shared understanding of antibiotics as precious
drugs but with a diminishing activity due to resistance, as well
as to create a favourable economic environment and opportun-
ities for the discovery of new agents. Reconciling these goals is
imperative if we want to have these powerful drugs available in
the future. There is also a clear awareness that such an endeavour
cannot succeed if it is cultivated and championed merely by one
sector of society, be it pharmaceutical companies, academia or
public health.9 It must find its roots among all of society’s players;
while these three sectors are integral, other stakeholders
(patients, clinical societies, government and payers) must play
an active and early role.
The DRIVE-AB Initiative
As outlined above, alternativemodels that can create incentives for
the R&D of novel antibiotics and yet reconcile these incentives with
responsible antibiotic use are long overdue.14 The IMI-funded,mul-
tistakeholder, E9.4 million DRIVE-AB (Driving Re-InVEstment in
R&D and responsible AntiBiotic use) consortium, composed of 14
public and 9 private partners from 12 countries (Table 1), will pro-
duce suchmodels in a stepwise yet interconnected process. First, it
will develop an evidence-based, consensus definition for ‘respon-
sible antibiotic use’, which, with its standardized quality and quan-
tity indicators, will provide the framework for later steps. Next, data
from surveillance systems and published literature will inform esti-
mations of the present burden of antibiotic resistance from both
clinical and economic perspectives across varying socioeconomic
backdrops. Simulation models informed by these data as well as
data from past and ongoing epidemics will estimate current and
future public health needs and impact related to antibiotic resist-
ance, in diverse socioeconomic settings. Together, these constructs
will allow for valuation models that will estimate the real worth of
new and existing antibiotics from the perspectives of patients, phy-
sicians, payers and society as awhole. These, in turn, will inform the
creation of alternative economic strategies and rewardmodels that
will promote and sustain the development of novel antibiotics
while simultaneously bolstering the appropriate consumption of
existing and novel antibiotics. The most promising schemes will
be presented to and tested with policy-makers and other stake-
holders with attendant implementation and risk-management
strategies.
What makes the DRIVE-AB project unique? As they work
together over the next 3 years, theworldwide renowned expertise,
motivation and diversity of the DRIVE-AB partners will be an
appropriate match for the complexity and scope of the problem
to be confronted. The innovative economic models will be, for
the first time, extensively tested in real-time quantitative scen-
arios to provide reliable data for policy-making.14 To facilitate
the implementation of new models, DRIVE-AB will convene the
first large international stakeholder platform of experts and advis-
ory groups. This unprecedented coalition will combine experience
and knowledge spanning all phases of antibiotic R&D, financing,
clinical use and stewardship, in order to drive a better understand-
ing of antibiotics as a common good. The development of models
for a favourable economic environment linked to appropriate
usage and global access will finally contribute to replenished pipe-
lines and the availability of novel antibiotics that are effective
against infections caused by resistant bacteria.
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